Skip to main content

Table 3 Prognostic impact of hormone receptor and HER-2 status in patients with brain metastases from breast cancer

From: Prognostic indices for brain metastases – usefulness and challenges

 

n

Prognostic impact of hormone receptor status

Prognostic impact of HER-2 status

Claude et al.51

120

none

not examined

Bartsch et al.52

174

none

None

Le Scodan et al.19

117

receptor negative significantly worse

None

Nam et al.53

126

receptor negative significantly worse

HER-2 negative significantly worse

Kirsch et al.54

95

not examined

HER-2 negative significantly worse*

Eichler et al.55

83

none

HER-2 negative significantly worse^

Melisko et al.56

112

receptor negative significantly worse

none

Harputluoglu et al.57

144

none

none

Park et al.58

125

none

HER-2 positive significantly worse

Church et al.59

86

not examined

HER-2 negative significantly worse*

  1. ^80% of HER-2 overexpressing cases received trastuzumab after diagnosis of brain metastases
  2. * the difference in survival was limited to patients with HER-2 overexpressing cancer treated with trastuzumab after diagnosis of brain metastases